Polyrizon (PLRZ) Stock Price, News & Analysis

Company Overview

Polyrizon Ltd. is a development stage biotech company specializing in the development of medical device hydrogels delivered in the form of nasal sprays. Polyrizon Ltd. is based in Raanana, Israel.

Key Stats

• Today's Range: $13.71 to $15.34
• 50-Day Range: $9.72 to $15.31
• 52-Week Range: $2.88 to $18.20
• Volume: 274,070 shs
• Average Volume: 64,579 shs
• Market Capitalization: $30.83 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Polyrizon Stock Analysis - MarketRank™

Polyrizon scored higher than 5% of companies evaluated by MarketBeat, and ranked 900th out of 916 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Polyrizon has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Polyrizon has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Polyrizon has a P/B Ratio of 1.11. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.53% of the float of Polyrizon has been sold short.

Short Interest Ratio / Days to Cover

Polyrizon has a short interest ratio ("days to cover") of 1.59, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Polyrizon has recently increased by 48.79%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Polyrizon does not currently pay a dividend.

Dividend Growth

Polyrizon does not have a long track record of dividend growth.

News and Social Media

• Score: 1.5 / 5
• News Sentiment: 0.43

News Sentiment

Polyrizon has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.98 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Polyrizon this week, compared to 3 articles on an average week.

Search Interest

Only 4 people have searched for PLRZ on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Polyrizon insiders have not sold or bought any company stock.

Percentage Held by Institutions

Polyrizon has minimal institutional ownership at this time.

Company Calendar

• Today: 9/01/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:PLRZ
• Previous Symbol: NASDAQ:PLRZ
• CIK: 1893645
• Web: www.polyrizon-biotech.com
• Phone: 972-55-433-5665
• Fax: N/A
• Employees: N/A
• Year Founded: 2005

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 29.03
• Quick Ratio: 29.03

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $13.05 per share
• Price / Book: 1.14

Miscellaneous

• Outstanding Shares: 2,080,000
• Free Float: N/A
• Market Cap: $30.83 million
• Optionable: N/A
• Beta: -1.50